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Agrimony (Agrimonia eupatoria L.) (Ae) is used in traditional medicine to treat inflammatory and oxidative related diseases.
Therefore, this study focuses on the anti-inflammatory and analgesic potential of Ae infusion (AeI). Phenolic compounds
characterization was achieved by HPLC-PDA-ESI/MS𝑛. To evaluate antioxidant potential, 2,2-diphenyl-1-picrylhydrazyl (DPPH),
superoxide anion, hydroxyl radical, and SNAP assays were used. In vitro anti-inflammatory activity of AeI was investigated in
LPS-stimulated macrophages by measuring the NO production. In vivo anti-inflammatory activity was validated using the mouse
carrageenan-induced paw edema model. Peripheral and central analgesic potential was evaluated using the acetic acid-induced
writhing and hot-plate tests, respectively, as well as the formalin assay to assess both activities. The safety profile was disclosed in
vitro and in vivo, usingMTT and hematoxylin assays, respectively. Vitexin, quercetinO-galloyl-hexoside, and kaempferolO-acetyl-
hexosyl-rhamnoside were referred to in this species for the first time. AeI and mainly AePF (Ae polyphenolic fraction) showed a
significant antiradical activity against all tested radicals. Both AeI and AePF decreased NO levels in vitro, AePF being more active
than AeI. In vivo anti-inflammatory and analgesic activities were verified for both samples at concentrations devoid of toxicity.
Agrimony infusion and, mainly, AePF are potential sources of antiradical and anti-inflammatory polyphenols.
1. Introduction
Agrimonia eupatoria L., Rosaceae, commonly known as
agrimony, is an erect, perennial herb, up to 100 cm high,
mostly unbranched, with a cylindrical stem. The pinnate
leaves are serrated and covered with soft hairs. Flowers are
hermaphrodite with 5 yellow petals, arranged on slender,
terminal spikes. The fruit is surrounded by several rows of
soft, hook-shaped bristles [1].
The aerial parts of agrimony are used to prepare infusions,
decoctions, or tinctures (hydroalcoholic extracts) in tradi-
tional medicine, due to their antioxidant, anti-inflammatory,
astringent, and diuretic properties [2, 3]. Nonetheless, only a
small number of scientific works have been carried out con-
cerning these activities and the phytoconstituents involved.
Aromatic acids, triterpenes, and tannins have been cited
[4]. The presence of kaempferide, kaempferol, and their
derivatives, such as kaempferol 3-O-glucoside, kaempferol
3-O-rhamnoside, and kaempferol 3-O-rutinoside, has also
been reported [5, 6]. However, to our knowledge, little
scientific information has been published about some of its
phenolic compounds, namely, proanthocyanidins, and of the
recently discovered compounds like glycosylated flavonoid
phenolic acid esters, such as kaempferol 3-O-(2󸀠󸀠-O-acetyl-
6󸀠󸀠-p-coumaroyl)-glucoside [3, 7]. Condensed tannins, gen-
erally designed by proanthocyanidins, are a group of phy-
tochemicals that has been described as potent antioxidants.
Usually, the scavenging activity of those flavan-3-ol polymers
increases with the number of hydroxyls, especially if they are
in ortho position on B-ring, and for their gallic acid esters.
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Antiradical activity also increases frommonomers to trimers,
though it decreases afterwards [3].
Flavonoids belong to an extensive group of polyphenols,
and several biological activities, such as anti-inflammatory,
antiulcer, anticancer, antiviral, antibacterial, antispasmodic,
neuroprotective, antiatherosclerotic, and antithrombotic,
have been attributed to these compounds. Oxidative stress
and antioxidant defense have been associated with inflam-
matory, carcinogenic, and coronary diseases. The recog-
nized antioxidant potential of flavonoids could therefore be
responsible for their beneficial actions [8]. Moreover, anti-
inflammatory properties, which are sometimes correlated
with antioxidant activities, have also been verified for these
compounds [9–11].
Extensive research within the last two decades has
revealed that most chronic illnesses, including cancer, dia-
betes, and cardiovascular disease, are mediated through
chronic inflammation, which currently constitutes one of the
leading causes of mortality in western world [12]. Despite the
fact that the mechanisms by which it happens have not been
clarified yet, it is known that reactive species act as second
messengers triggering the aberrant expression of inflamma-
tory genes, such as cytokines, chemokines, cyclooxygenase-
2 (COX-2), and inducible nitric oxide synthase (iNOS). It is
also known that reactive species, ROS and RNS, can activate
signal transduction cascades as well as inducing changes
in transcription factors, which mediate immediate cellular
inflammatory and stress responses [12]. The main pathway
initiating this inflammatory process is the nuclear factor NF-
kB signaling pathway [13]. Inflammation is usually associated
with pain. In fact, many of the chemical mediators, namely,
histamine, serotonin, bradykinin, prostaglandins, TNF-𝛼,
and protons, generated during inflammation, stimulate the
nociceptive receptors responsible for peripheral pain [14].
Previous results demonstrated that an aqueous extract of
Agrimonia eupatoria exhibited a prominent free radical-
scavenging effect against DPPH radical [3, 15, 16] and also
against ABTS radical cation [17]. In general, the increase of
hydroxyl substitutions is correlated with a stronger antioxi-
dant activity [18].
Folk medicine from different countries also reports the
strong anti-inflammatory potential of A. eupatoria prepara-
tions [3], which was correlated with the reduction of TNF-
𝛼, IL-1𝛽, and IL-6 production in mouse cell cultures [19].
Additionally, it was also previously reported that agrimony
ameliorated the chronic ethanol-induced liver injury and that
protection was likely due to the suppression of oxidative
stress and Toll-like receptor- (TLR-) mediated inflammatory
signaling [20].
In our ongoing work, we characterized Agrimonia eupa-
toria hydroalcoholic extracts and proved that they have
pronounced antioxidant activity against reactive species,
mainly due to specific flavonoids and/or condensed tannins,
identified as flavonol, flavone, and flavan-3-ol derivatives [21,
22]. Accordingly, a recent study confirmed the presence of
these compounds in agrimony and among them are proan-
thocyanidins, apigenin, luteolin, quercetin, and kaempferol
derivatives, but also the catechin, chlorogenic acid, and p-
coumaric acid were identified [23].
This study aims to characterize the antioxidant activity
of the Agrimonia eupatoria L. infusion and a polyphenol-
enriched fraction and to correlate this bioactivity with its
phenolic profile. Besides, we aimed to assess the in vitro
anti-inflammatory activity of both the infusion and the
polyphenol-enriched fraction at concentrations devoid of
toxicity. The anti-inflammatory and analgesic properties of
these samples were validated using in vivo models, while the
liver and kidney toxicities weremonitored in order to support
the traditional use of this medicinal plant.
2. Materials and Methods
2.1. Plant Material, Extract, and Fractioning. Aerial parts
of Agrimonia eupatoria L. were provided by Segredo da
Planta, Portugal (batch number 5870 and quality control data
identifying no defects), identified by Dr. Ce´lia Cabral and
a voucher specimen (T. Batista 02009) was deposited at the
Herbarium of Medicinal and Aromatic Plants, Faculty of
Pharmacy, University of Coimbra.The extract (infusion) was
prepared according to the usages in traditional medicine; in
particular, 20 g of pulverized plant was infused in 600mL
of water, for 15min. The infusion was then vacuum-filtered
and washed with n-hexane (1 : 1) to eliminate the fat-soluble
compounds. Next, a half of the infusion was concentrated in
a Rotavapor at 30∘C, frozen, and freeze-dried (AeI), while
the other half was fractionated by repeated extraction with
ethyl acetate (Merck, Darmstadt, Germany) (3 × 225mL).
The organic phases, containing polyphenols, were collected,
dehydrated with anhydrous sodium sulfate, and concentrated
with water, in a Rotavapor at 30∘C, until all the ethyl acetate
had been removed. Ethyl acetate fraction was frozen and
freeze-dried (AePF).
2.2. HPLC-PDA-ESI/MSn. AeI and AePF were analyzed by a
Surveyor liquid chromatograph equippedwith a photodiodes
(PDA) detector (Surveyor) and interfaced with a Finnigan
LCQ (San Jose, CA, USA) mass spectrometer equipped with
an API-ES ionization chamber. Separation was performed
on an Spherisorb ODS-2 C18 reverse phase column, 150
× 2.1mm i.d. and size particle of 3 𝜇m, (Waters Corpora-
tion, Milford, Massachusetts, USA) and a Spherisorb ODS-
2 guard cartridge C18 (10 × 4.6mm i.d. and size particle of
5 𝜇m; Waters Corporation [Milford, Massachusetts, USA])
at 25∘C, using 2% aqueous formic acid (A) and methanol
(B) as mobile phase. The gradient profile used was 5–15%
B (0–10min), 15–30% B (10–15min), 30–35% B (15–25min),
35–50% B (25–35min), 50–80% B (35–40min), and 80%
B (40–60min), isocratically, at a flow rate of 0.2mL/min.
The first detection was done with the PDA detector in
a wavelength range of 200–600 nm, followed by a second
detection in the mass spectrometer.
Mass analyses were obtained in the negative ion mode.
The mass spectrometer was programmed to perform three
consecutive scans: full mass MS1 (m/z 160–1300), MS2 of the
most abundant ion inMS1, andMS3 of themost abundant ion
in MS2. Source voltage was 4.5 kV and capillary voltage and
temperature were −10V and 250∘C, respectively. Nitrogen
was used as sheath gas at flow rate of 20 arbitrary units.
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The normalized energy of collision was 45%, using helium as
collision gas.
2.3. Antioxidant Activity. Free radical-scavenging activity
was evaluated according to the method described by Blois,
1958 [24]. Aliquots of samples (100 𝜇L) were assessed by their
reactivity with methanolic solution of 500𝜇M DPPH (2,2-
diphenyl-1-picrylhydrazyl) (500 𝜇L) (Sigma-Aldrich, Portu-
gal) in the presence of 100mM acetate buffer, pH 6.0 (1mL).
Reaction mixtures (3mL) were kept for 30min at room
temperature and in the dark.The decreases in the absorbance
were measured at 517 nm, in a Cintra 101, GBC (Victoria,
Australia) spectrophotometer. Butylhydroxytoluene (BHT)
(Sigma-Aldrich, Portugal) was used as reference compound.
Data treatment and statistical analysis were achieved using
Microsoft Excel 2013.
The assay was based on the superoxide-driven reduc-
tion of nitroblue tetrazolium (NBT) by photochemically
reduced riboflavin [25]. Reaction mixtures (3mL) con-
tained phosphate buffer (16mM, pH 7.8), 0.1mM ethylenedi-
aminetetraacetic acid (EDTA), 0.8mM tetramethylethylene-
diamine (TEMED), 85 𝜇M nitroblue tetrazolium (NBT),
6 𝜇M riboflavin, and the appropriate volume of the samples.
The assay was carried out at room temperature (22∘C) under
fluorescent lighting (20W, 20 cm). Reaction was stopped by
switching off the light and the addition of 50 𝜇L of 1mg/mL
superoxide dismutase (SOD). Absorbance was measured at
560 nm. Quercetin was used as reference compound.
The scavenging capacity for hydroxyl radical was eval-
uated using a deoxyribose degradation assay performed
according to the procedure described by Paya´ et al. [26]. In
a final volume of 1mL, reaction mixtures contained 20mM
phosphate buffer (pH 7.4), 2.8mM2-deoxy-D-ribose, 104 𝜇M
EDTA, 20𝜇M FeCl3, 0.5mM H2O2, 0.1mM ascorbic acid,
and the sample aliquots. Mixtures were kept at 37∘C for
1 h and, then, the extent of deoxyribose degradation was
measured by adding 1mL of 1% thiobarbituric acid (TBA)
(w/v) and 1mL of 2.8% trichloroacetic acid (TCA) (w/v),
followed by heating at 100∘C for 20min. After cooling,
absorbance was measured at 532 nm. Quercetin was used as
reference.
2.4. In Vitro Assays. Raw 264.7, a mouse leukaemic mono-
cyte macrophage cell line from American Type Culture
Collection, kindly supplied by Dr. Ot´ılia Vieira (Centro de
Neurocieˆncias e Biologia Celular, Universidade de Coimbra,
Coimbra, Portugal), was cultured in Iscove’s Modified Dul-
becco’s Eagle Medium supplemented with 10% noninacti-
vated fetal bovine serum, 100U/mLpenicillin, and 100 𝜇g/mL
streptomycin at 37∘C in a humidified atmosphere of 95% air
and 5%CO2. Along the experiments, cells were monitored by
microscope observation in order to detect anymorphological
change.
Assessment of metabolically active cells was performed
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) reduction colorimetric assay as previously
reported [27]. Raw 264.7 cells (6 × 105 cells/well) were plated
(48-well plate) and allowed to stabilize for 12 h. Following
this period, cells were either maintained in culture medium
(control) or preincubated with the sample for 1 h and later
activated with 1 𝜇g/mL LPS (Sigma Chemical Co., USA) for
24 h. After the treatments, a MTT solution (5mg/mL in
phosphate buffered saline) was added and cells incubated
at 37∘C for 15min, in a humidified atmosphere of 95% air
and 5% CO2. Supernatants were then removed and dark
blue crystals of formazan solubilized with acidic isopropanol
(0.04NHCl in isopropanol). Quantification of formazan was
performed using an ELISA automaticmicroplate reader (SLT,
Austria) at 570 nm, with a reference wavelength of 620 nm.
Data are expressed as mean ± SEM. Statistical significance
was determined by one-way ANOVA, followed by Dunnett’s
post hoc test.
The production of nitric oxide (NO) was measured by
the accumulation of nitrite in the culture supernatants,
using a colorimetric reaction with the Griess reagent [28].
Briefly, 170 𝜇L of culture supernatants was diluted with equal
volumes of the Griess reagent [0.1% (w/v) N-(1-naphthyl)-
ethylenediamine dihydrochloride and 1% (w/v) sulphanil-
amide containing 5% (w/v) H3PO4] and maintained during
30min, in the dark. The absorbance at 550 nm was measured
in an automated plate reader (SLT, Austria). Culture medium
was used as blank and nitrite concentration was determined
from a regression analysis using serial dilutions of sodium
nitrite as standard. Data are expressed as mean ± SEM.
Statistical significance was determined by one-way ANOVA,
followed by Dunnett’s post hoc test.
The nitric oxide (NO) scavenging activity was evalu-
ated by incubating the samples with 150 𝜇M of NO donor
S-nitroso-N-acetylpenicillamine (SNAP; Tocris Bioscience,
Bristol, UK), in Iscove’s Modified Dulbecco’s Eagle Medium
(Sigma-Aldrich Quı´mica, Madrid, Spain). The concentration
of the samples was chosen based on the EC50 concentration
of DPPH radical-scavenging results. After 3 h, the nitrite
levels in the medium were quantified by Griess method,
as described above. Data are expressed as mean ± SEM.
Statistical significance was determined by one-way ANOVA,
followed by Dunnett’s post hoc test.
2.5. In Vivo Assays. Male Wistar rats weighing 160–220 g
and male mice weighing 25–30 g were obtained from Charles
River (Barcelona, Spain). The animals were maintained with
food and water ad libitum and kept at 22 ± 1∘C with
controlled 12-hour light/dark cycle at Faculty of Pharmacy,
University of Coimbra. The animals were allowed to adapt to
the laboratory for 7 days before testing. For evaluation of the
anti-inflammatory activity, rats were fasted with free access to
water at least 24 h prior to experiments. To study the analgesic
activity of the samples, mice were fasted with free access to
water at least 18 h prior to experiments. The research was
conducted in accordance with the internationally accepted
principles for laboratory animal use and care as found in
Directive 2010/63/EU and the project was approved by the
Portuguese Veterinary General Division.
Agrimonia eupatoria infusion (AeI) and its ethyl acetate
fraction (AePF) were dissolved in distilled water and the
administrated doses were calculated based on the tradi-
tionally used doses (extract of 5 g of plant in 150mL of
water), taking into account our yield of the extraction by
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infusion and by ethyl acetate fractioning process, as well
as the conversion into animal doses, according to the FDA
(Food and Drug Administration) guidelines, “Estimating the
Safe Starting Dose in Clinical Trials forTherapeutics in Adult
Healthy Volunteers” [29]. In order to examine a possible
dose-dependent effect, two different doses were used: D1
and D2 (in the inflammation assay) and D2 and D3 (in
both pain evaluation assays), according to the animal model
used. During the experimental studies, procedures to reduce
experimenter subjectivity and increase bias were followed.
2.5.1. Anti-Inflammatory Activity. For the experimental eval-
uation of anti-inflammatory activity, the animals were anes-
thetized with a solution of sodium ketamine (Ketalar,
50mg/kg) purchased fromParke-Davis, Pfizer (Seixal, Portu-
gal) and chlorpromazine (Largactil, 2.3mg/kg) fromRhoˆne-
Poulenc Rorer, Laborato´rio Vito´ria SA (Amadora, Portugal).
The carrageenan-induced rat paw edema test [27] was
used to evaluate the in vivo acute anti-inflammatory activ-
ity of the AeI and AePF, employing diclofenac sodium as
reference drug. Rat paw edema was assessed by the volume
displacement method resorting to a digital Plethysmometer
(model LE7500, Panlab, Barcelona, Spain). Before the attain-
ment of the experiment, a preassay was carried out in order
to ascertain in which time occurs the maximum of edema
volume, in other words, the maximum of inflammation.
For that, a subplantar injection of 0.1mL of 1% solution of
carrageenan in saline, administered to the right hind footpad
of each animal, was carried out, and the paw volume was
measured in intervals of 30min. in a period of 7 h.The results
of this experiment showed us that themaximum value of paw
edema occurs 4 h after the carrageenan administration, being
this the period of time used for the following experiment.
The rats were divided into four groups (𝑛 = 6–8): car-
rageenan negative control group received water 0.5𝜇L/g p.o.,
positive control group received diclofenac sodium 10mg/kg
i.p., and test groups received orally AeI (99.59mg/kg, D1,
and 199.18mg/kg, D2) and AePF (18.12mg/kg, D1, and
36.24mg/kg, D2) reconstituted in water. Negative control
and test groups, respectively, were dosed with the vehicle
and samples, 1 h, and positive control group was dosed with
diclofenac sodium, 30min before the administration of a
subplantar injection of 0.1mL of 1% solution of carrageenan
in saline, to the right hind footpad of each animal. The
potential anti-inflammatory was calculated 4 h after car-
rageenan administration and was expressed as percentage
of edema inhibition, for the treated animals, in relation to
the carrageenan control group. The percentage of edema
inhibitionwas calculated according to the following equation:
% edema inhibition = 1 − (𝑉𝑡/𝑉𝑐) × 100, where 𝑉𝑡 is the mean
variation in paw volume in rats treated with the AeI, AePF,
or diclofenac sodium and 𝑉𝑐 is the mean variation in paw
volume in the carrageenan control group. Data are expressed
as mean ± SEM. Statistical significance was determined by
one-way ANOVA, followed by Tukey’s post hoc test.
2.5.2. Central Analgesic Activity. The hot-plate test was used
to evaluate the central analgesic activity of the AeI and
AePF by measuring the reaction time according to the
methoddescribed byEddy andLeimbach [30].Morphinewas
used as reference drug. The mice were placed individually
on a hot-plate set at 55 ± 1∘C (model LE7406, PanLab,
Barcelona, Spain). Reaction time, measured in seconds, was
recordedwhen the animals licked their forepaws and jumped.
The baseline was considered as being the reaction time
before treatment and was measured 24 h previous to the
experiment. Mice were then divided randomly into five
groups (𝑛 = 6–8): positive control group received morphine
hydrochloride 10mg/kg i.p. and test groups received orally
the AeI (199.18mg/kg, D2, and 398.26mg/kg, D3) and the
AePF (36.24mg/kg, D2, and 72.48mg/kg, D3) reconstituted
in water. Test groups were dosed 1 h and positive control
group was dosed 30min before placement on the hot plate
for recording of reaction time to temperature. The cut-off
time was set at 30 s to protect the animals. The percentage
of analgesic capacity was calculated by using the formula:
% analgesic capacity = 1 − (𝑇𝑏/𝑇𝑡) × 100, where 𝑇𝑏 is the
mean reaction time recorded as baseline and 𝑇𝑡 is the mean
reaction time recorded after treatmentwithmorphine orwith
the sample. Data are expressed as mean ± SEM. Statistical
significance was determined by one-way ANOVA, followed
by Tukey’s post hoc test.
2.5.3. Peripheral Analgesic Activity. The acetic acid-induced
writhing test was carried out according to the method
previously described by Collier et al. [31].The test was used to
evaluate the peripheral analgesic activity of the AeI andAePF,
employing diclofenac sodium as reference drug. Acetic acid
at 0.6% in saline was administered i.p. 0.1mL/10 g b.w. The
number of writhes, a response consisting of the contraction
of the abdominal wall followed by hind limb extension, was
counted during continuous observation of the animals for
30min, starting the count 5min after the injection. The
animals were divided into six groups (𝑛 = 6–8): negative
control group received water 0.5 𝜇L/g p.o., positive control
group received diclofenac sodium 10mg/kg i.p., and test
groups received the AeI and AePF at the doses referred to
above. Negative control and test groups were dosed 1 h and
positive control group was dosed 30min before the acetic
acid injection. A significant reduction in the number of
writhes by any drug was considered as a positive analgesic
response. Percent analgesic capacity was calculated by using
the formula: % analgesic capacity = 1 − (𝑊𝑡/𝑊𝑐) × 100, where
𝑊𝑡 is the average number of writhes in test and positive
control groups and𝑊𝑐 is the average number of writhes in the
negative control group. Data are expressed as mean ± SEM.
Statistical significance was determined by one-way ANOVA,
followed by Tukey’s post hoc test.
2.5.4. Analgesic Activity. The formalin test was carried out
according to the method previously described by Hunskaar
andHole [32].The test was used to evaluate either the periph-
eral or the central analgesic activity of the sample, employing,
respectively, diclofenac sodium or morphine hydrochloride
as reference drugs. Mice were divided into four groups (𝑛 =
6–8): a test group (72.48mg/kg of the AePF p.o.), a negative
control group (water p.o.), an early phase positive control
group (morphine hydrochloride 10mg/kg i.p.), and a late
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Figure 1:HPLCprofile ofAgrimonia eupatoriapolyphenol-enriched ethyl acetate fraction (AePF).The chromatographic profilewas registered
at 280 nm. For experimental conditions, see Materials and Methods.
phase positive control group (diclofenac sodium 10mg/kg
i.p.). After 1 hour, for the test group and the negative control
group, or 30min, for the positive controls, the animals were
subcutaneously injected with 20 𝜇L of 1% formalin in 0.9%
saline into the dorsal hind paw and placed immediately
inside a transparent box for observation. The duration of
paw lickingwas determinedwithin 0–5min (early phase) and
20–40min (late phase) after the formalin injection. The time
spent licking, in seconds, was noted.
The analgesic capacity (in percentage) was calculated by
using the formula: % analgesic capacity = 1 − (𝑊𝑡/𝑊𝑐) × 100,
where𝑊𝑡 is the average time spent licking in test and positive
control groups and𝑊𝑐 is the average time spent licking in the
negative control group. Data are expressed as mean ± SEM.
Statistical significance was determined by one-way ANOVA,
followed by Tukey’s post hoc test.
Five hours after administration of the samples, the rats
used in the paw edema test were sacrificed. Livers and kidneys
were collected, cut into transverse fragments (0.5 cm), and
immersed in a 10% solution of formaldehyde in a 24 h period.
The pieces were processed into paraffin and stored at −20∘C.
The fragments were cut in 4 𝜇mpieces in a Shandon (AS 325)
microtome and stained with hematoxylin (cell nuclei, blue)
and eosin (cytoplasm, pink/red). The resulting images were
obtained and observed (20x magnification in the original) in
a Nikon (Eclipse E600) microscope.
3. Results and Discussion
In the present study, the main polyphenols of Agrimonia
eupatoria aerial part infusion were identified, the results
demonstrating their contribution for the antioxidant, anti-
inflammatory, and analgesic activities.
3.1. HPLC-PDA-ESI/MSn. HPLC profiles were recorded at
280 nm for all samples, Figure 1 showing the HPLC profile
from Agrimonia eupatoria polyphenol-enriched ethyl acetate
fraction (AePF). Absorption maxima and ultraviolet profiles
obtained with the diode array detector allowed most peaks
to be identified as flavan-3-ols (1–10), quercetin (14, 17-18),
kaempferol (21, 23–26), apigenin (13, 15, 19, and 22), and
luteolin (16) derivatives and, in lesser extent, agrimoniin (11),
p-coumaric acid (12), and ellagic acid (20). Table 1 summa-
rizes retention times, UV spectra maxima, MS𝑛 fragments of
relevant peaks and, on this basis, the tentative identification
of the polyphenols present in the samples.
HPLC-PDA-ESI/MS𝑛 analysis of AePF revealed the pres-
ence of procyanidins and flavonoids as the most relevant
compounds of this fraction. Phenolic acids have been iden-
tified, namely, p-coumaric acid and ellagic acid, as described
previously [21]. Many flavonoids were characterized by both
PDA and MS detectors. Isovitexin, hyperoside [19], iso-
quercitrin, tiliroside [6], and other flavones and flavonols
derivatives were found in this plant. To our knowledge,
vitexin, quercetin O-galloyl-hexoside, and kaempferol O-
acetyl-hexosyl-rhamnoside were found in this species for the
first time. Interestingly, antiradical and/or anti-inflammatory
activities have been reported for these three flavonoids [33–
35].
3.2. Antioxidant Activity. As shown in Table 2, Agrimonia
eupatoria infusion (AeI) and its ethyl acetate fraction (AePF)
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Table 1: Phenolic characterization of AePF from Agrimonia eupatoria, by HPLC-PDA-ESI/MS𝑛.
Peak Rt (min) Tentativeidentification
𝜆max
(nm)
|M −H|−
(m/z)
MS2 MS3
[m/z (relative abundance, %)]
1 14.94 Procyanidindimer 279 577
451 (18), 425 (100),
407 (84) 407 (100), 273 (5)
2 16.48 Procyanidintrimer 278 865
739 (36), 713 (34),
695 (100), 577 (49),
543 (15), 425 (20),
407 (21), 405 (14)
677 (39), 543 (69),
525 (100)
3 17.48 Catechin∗ 279 289 245 (100), 205 (41),203 (16), 179 (7)
227 (34), 213 (11),
203 (100), 175 (17),
174 (11)
4 18.07 Procyanidindimer 279 577
451 (22), 425 (100),
407 (83), 289 (26)
407 (100), 381 (4),
245 (5)
5 18.25 Procyanidintrimer 279 865
739 (20), 695 (100),
587 (36), 577 (46),
575 (23), 451 (23),
425 (14), 407 (20)
525 (100), 203 (53)
6 18.94 Procyanidintetramer 279 1153
1057 (51), 983 (51),
965 (68), 863 (39),
813 (84), 713 (41),
695 (100), 617 (92)
—
7 19.78 Procyanidintetramer 279 1153
917 (99), 863 (88),
813 (86), 489 (100) —
8 20.01 Procyanidintrimer 280 865
739 (13), 738 (14),
695 (100), 587 (23),
577 (38), 569 (10),
543 (33), 407 (29)
677 (30), 585 (50),
525 (88), 407 (100)
9 21.10 Procyanidindimer 279 577
451 (12), 425 (100),
407 (75) —
10 21.65 Procyanidintrimer 280 865
739 (34), 738 (11),
695 (100), 587 (28),
577 (51), 569 (20),
561 (24), 543 (21),
451 (17), 407 (22)
525 (83), 407 (100)
11 23.01 Agrimoniin 258sh, 282 935§
899 (3), 633 (100),
523 (2), 463 (5), 301
(93)
301 (100)
12 25.47 p-Coumaricacid∗ 298sh, 310 — — —
13 31.01
Apigenin
8-C-glucoside
(vitexin)
270, 331 431 341 (3), 311 (100) 293 (3), 283 (100),239 (4)
14 34.07 Quercetin O-galloyl-hexoside
259sh, 265,
342 615
463 (100), 301 (9),
300 (3)
301 (100), 300 (93),
296 (2), 283 (2), 179
(1)
15 34.85
Apigenin
6-C-glucoside
(isovitexin)∗
270, 333 431
413 (17), 395 (1),
383 (2), 355 (1), 341
(54), 311 (100)
283 (100)
16 35.50
Luteolin
7-O-glucoside
(Cynaroside)∗
268, 295sh,
348 447 327 (6), 285 (100)
285 (100), 257 (85),
242 (37), 241 (42),
217 (60), 198 (62)
17 36.19
Quercetin
3-O-glucoside
(isoquercetin)∗
256,
266sh, 355 463 301 (100), 179 (3)
273 (12), 271 (100),
257 (15), 255 (61),
179 (98)
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Table 1: Continued.
Peak Rt (min) Tentativeidentification
𝜆max
(nm)
|M −H|−
(m/z)
MS2 MS3
[m/z (relative abundance, %)]
18 37.35
Quercetin
O-malonyl-
hexoside
259, 267sh,
348 549
505 (100), 464 (1),
387 (1)
463 (27), 342 (10),
301 (100)
19 38.27
Apigenin
7-O-glucoside
(apigetrin)∗
258sh, 265,
331 431
311 (11), 269 (100),
268 (22) 159 (100)
20 38.77 Ellagic acid 257, 351 301 257 (100), 179 (2),151 (2) 179 (100), 151 (60)
21 39.42
Kaempferol
3-O-glucoside
(astragalin)∗
265, 346 447 327 (12), 285 (100),255 (15)
257 (16), 256 (21),
255 (100), 227 (13)
22 40.86 ApigeninO-glucuronide
258sh,
264, 331 445
307 (10), 269 (100),
175 (20) 225 (40), 185 (63)
23 41.53
Kaempferol
O-malonyl-
hexoside
257sh, 264,
340 533 489 (100) 285 (100)
24 42.31 KaempferideO-rhamnoside
265, 311,
348 445 298 (100), 283 (5)
269 (100), 207
(22), 191 (7), 187
(4), 163 (24), 148
(6)
25 42.92
Kaempferol
O-p-coumaroyl-
glucoside
(tiliroside)
267, 290sh,
315, 349 593
447 (15), 429 (2),
323 (1), 285 (100),
284 (3), 257 (3)
267 (32), 257 (82),
243 (100), 211 (57)
26 43.56
Kaempferol O-
acetyl-hexosyl-
O-rhamnoside
267, 294sh,
315, 348 635
575 (21), 489 (20),
431 (11), 349 (5),
285 (100), 255 (3)
257 (100), 255 (42),
240 (8), 213 (9), 183
(9), 151 (21)
sh: shoulder; §|M − 2H|2−; ∗confirmed by commercial reference compounds.
Table 2: Free radical scavenging effect of AeI and AePF from
Agrimonia eupatoria.
Sample EC50
a
DPPH radical Superoxide anion Hydroxyl radical
AeI 12.80 ± 0.05 13.59 ± 1.03 126.99 ± 11.97
AePF 4.60 ± 0.05 3.34 ± 0.20 90.97 ± 8.29
BHT 4.67 ± 0.05 — —
Quercetin — 5.34 ± 0.43 15.74 ± 1.31
aAmount of the samples (𝜇g/mL of reaction mixture) that decreased 50% of
the absorbance values as compared to the negative control. Each value is the
mean ± SD of the three replicates.
exerted a significant scavenging effect, reacting with the
DPPH free radical. AePF was the most potent sample with
an EC50 of 4.60 𝜇g/mL, followed by AeI with an EC50 value of
12.80 𝜇g/mL.
Superoxide anion scavenging activity was observed for
two samples, the most active being the AePF, which evi-
denced an EC50 of 3.34 𝜇g/mL. AeI exhibited a higher EC50,
13.59 𝜇g/mL (Table 2).
AePF was the most potent sample concerning the
hydroxyl radical-scavenging effect, showing an EC50 of
90.97 𝜇g/mL. AeI showed an EC50 value of 126.99 𝜇g/mL
(Table 2).
Concerning the antioxidant bioactivity, our results
demonstrated that AePF was more active against DPPH,
superoxide, and hydroxyl radical than the infusion.
Therefore, the ethyl acetate extraction proved to be an
efficient technique to extract compounds that confer
antioxidant properties to Agrimonia eupatoria infusion. In
fact, the effects of AePF on DPPH and superoxide anion
were, respectively, similar to that of the BHT, a synthetic
antioxidant, and higher than quercetin, a potent natural
antioxidant. These results are in accordance with previously
described data for kaempferol, quercetin, and tiliroside,
exhibiting important DPPH and superoxide scavenging
activities [35–37]. On the other hand, weaker activities
against the hydroxyl radical were observed, corroborating
what is cited in literature.
3.3. In Vitro Assays. The cytotoxic effect of AeI and AePF
on RAW 264.7 macrophages was reported to percentage of
lipopolysaccharide (LPS) showing that only the higher con-
centrations tested forAeI (770𝜇g/mL) andAePF (276𝜇g/mL)
decrease the cell viability (Figure 2(a)).
The effect on NO production was analyzed by measuring
nitrite accumulation in the culture medium of macrophages
stimulated with LPS. As shown in Figure 2(b), incubation
of macrophages with LPS, for 24 h, resulted in a significant
increase in nitrite production compared to the control.
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Figure 2: (a) Cell viability (% of LPS) of Raw 264.7 cells incubated with AeI (193, 382 and 770 𝜇g/mL) or AePF (69, 138 and 276 𝜇g/mL) for 1 h,
followed by incubation with LPS for 24 h. Data represent mean ± SEM of 3 independent assays. ∗∗∗𝑃 < 0.001, compared to control with LPS.
(b) Nitrite production (% of LPS) of Raw 264.7 cells after incubation with AeI (193, 382, and 770𝜇g/mL) or AePF (69, 138, and 276 𝜇g/mL) for
1 h, followed by incubation with LPS for 24 h. Data represent mean ± SEM of 3 independent assays. ∗∗∗𝑃 < 0.001 and ∗𝑃 < 0.05, compared
to control with LPS. (c) Nitrite production (% of SNAP) after incubation of SNAP with AeI (193 and 382 𝜇g/mL) or AePF (69 and 138 𝜇g/mL)
for 3 h. Data represent mean ± SEM of 3 independent assays. ∗𝑃 < 0.05, compared to control with SNAP.
Taking into account the toxicity of AeI and AePF for
the concentrations 770 𝜇g/mL and 276𝜇g/mL, respectively,
whichwas discussed in the previous section, inhibition ofNO
production was only considered for nontoxic concentrations
of the samples. Therefore, the AeI and AePF, for concentra-
tions of 382 𝜇g/mL and 138 𝜇g/mL, reduced NO production
relatively to LPS without detrimental effects to cells (11.34%
and 22.46% of inhibition, resp.).
Only the samples which did not affect cell viability on
the MTT assay were tested in the SNAP method used to
evaluate the NO-scavenging capacity of the samples. For
the concentrations tested, both AeI and AePF decreased the
levels of nitrites in the culture medium (Figure 2(c)). AeI
showed to significantly inhibit the SNAP activity by 36.67%,
at a concentration of 382 𝜇g/mL. AePF decreased nitrites
levels in a greater extent, with an inhibition of 29.46%, at a
concentration of 138𝜇g/mL.
Nitric oxide is a proinflammatory mediator involved in
inflammatory-related diseases [38]. Therefore, a decrease in
nitric oxide levels is an important strategy to ameliorate
inflammation. Both AeI and AePF slightly decreased nitric
oxide levels in vitro. In the SNAP assay, both samples (AeI and
AePF) showedNO-scavenging properties with no statistically
significant differences between their equivalent doses. This
suggests that the mechanism behind nitrite levels reduction
observed on the macrophages culture may be due to the
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Table 3: Effect of AePFD3 on the time that mice spent licking their hind paw during early and late phase of formalin test.
Group Dose (mg/kg) Time spent licking (0–5 min) Time spent licking (20–40 min) Pain reduction (%)
Control — 56.00 ± 4.05 183.80 ± 16.07 —
Reference 10 3.67 ± 0.76∗ 30.40 ± 5.77∗ 98.4
AePFD3 72.48 48.17 ± 3.19 124.00 ± 6.35∗ 32.5
Reference: morphine hydrochloride (10mg/kg b.w.) for early phase or diclofenac sodium (10mg/kg b.w.) for late phase; AePFD3: ethyl acetate fraction of the
aqueous extract at dose 72.48mg/kg b.w. Each value is the mean ± SEM of 6–8 rats. Statistical differences between the treated and the control groups were
determined by ANOVA followed by Tukey’s test. ∗𝑃 < 0.05 compared with control.
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Figure 3: Carrageenan-induced rat paw edema test. Results were
obtained by oral administration of an aqueous extract at doses
99.59mg/kg b.w (AeID1) and 199.18mg/kg b.w. (AeID2) and ethyl
acetate fraction of the aqueous extract at doses 18.12mg/kg b.w.
(AePFD1) and 36.24mg/kg b.w. (AePFD2) and 10mg/kg (i.p.)
of diclofenac sodium. Each value is mean ± SEM. of 6–8 rats.
Statistical differences between the treated and the control groups
were determined by ANOVA followed by Tukey’s test. ∗𝑃 < 0.05
compared with control.
NO-scavenging effect of the compounds present in AeI and
AePF.
3.4. In Vivo Assays
3.4.1. Anti-Inflammatory Activity. Carrageenan-induced paw
edema was significantly reduced 4 h after the administration
of the samples. The infusion reduced the edema by 43.2%
(AeID1) and 52.2% (AeID2) and the polyphenol-enriched
fraction reduced by 34.6% (AePFD1) and 35.4% (AePFD2)
(Figure 3).
3.4.2. Central Analgesic Activity. The results reveal that the
mice treated with both doses of agrimony did not show any
significant increase in the reaction time when in contact
with the hot plate (Figure 4). In fact, at AeID2, the mean
reaction time (±SEM)was 5.84 (±0.50) and at AeID3was 6.20
(±0.77). For AePFD2, the mean reaction time (±SEM) was
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Figure 4: Hot-plate test. Results were obtained by oral adminis-
tration of aqueous extract at doses 199.18mg/Kg b.w (AeID2) and
398.26mg/Kg b.w. (AeID3) and ethyl acetate fraction of the aqueous
extract at doses 36.24mg/Kg b.w. (AePFD2) and 72.48mg/Kg b.w.
(AePFD3) and 10mg/Kg (i.p.) of morphine hydrochloride. Each
value is the mean ± SEM of 6–8 rats. Statistical differences between
the treated and the control groups were determined by ANOVA
followed by Tukey’s test. ∗𝑃 < 0.05 compared with control.
5.17 (±1.18) and at AePFD3 was 4.16 (±0.49).Themice treated
withmorphine showed amarked increase in the reaction time
to 23.05 (±2.72).
3.4.3. Peripheral Analgesic Activity. The results presented
in Figure 5 show that agrimony produces an inhibition of
abdominal writhing induced by acetic acid in mice. The
reference drug induced an inhibition of 71.3%. The mice
treated with AeID2 and AeID3 showed a reduction of 43.5%
and 49.8% on the average number of abdominal constric-
tions, respectively, whereas, with AePFD2 and AePFD3, the
reduction was, respectively, 29.2% and 46.8%.
3.4.4. Analgesic Activity. In the formalin test, only the
AePFD3 dose was tested. It did not show any relevant effect
in the early phase of pain response but induced a reduction
of 32.5% in time spent licking on late phase (Table 3).
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Figure 5: Acetic acid-induced writhing test. Results were obtained
by oral administration of aqueous extract at doses 199.18mg/Kg
b.w (AeID2) and 398.26mg/Kg b.w. (AeID3) and ethyl acetate
fraction of the aqueous extract at doses 36.24mg/Kg b.w. (AePFD2)
and 72.48mg/Kg b.w. (AePFD3) and 10mg/Kg (i.p.) of diclofenac
sodium. Each value is the mean ± SEM of 6–8 rats. Statistical differ-
ences between the treated and the control groups were determined
by ANOVA followed by Tukey’s test. ∗𝑃 < 0.05 compared with
control.
The liver and renal tissues of animals treated with the
samples did not show differences resulting from toxic effects,
comparatively to the animals of the control group (Figure 6).
In the experimental models used in in vivo assays, the
samples presented a significant effect for the carrageenan-
induced rat paw edema reduction. Also in this case, there are
no significant differences between the equivalent doses of AeI
and AePF.This is in accordance with the above results for the
SNAP assay. Besides, although there is a tendency for a reduc-
tion on the inflammation values with the increased dose of
AeI, there are no statistically significant differences between
AeID1 and AeID2 and between AePFD1 and AePFD2. This
may suggest that, for the tested concentrations, the anti-
inflammatory activity of the compounds has already reached
their maximum plateau. This hypothesis is supported by the
fact that the doses usedwere calculated based on those among
the highest one referred to in traditional medicine.
Diclofenac sodium is a common nonsteroid anti-inflam-
matory drug (NSAID) well known for its anti-inflammatory
and analgesic activities. As agrimony presented ability to
inhibit the swelling of the animal’s paw, this suggests that its
anti-inflammatory effect may be related to the inhibition of
the synthesis and release of various inflammatory mediators
and to its antioxidant activity and reactive oxygen and
nitrogen species scavenging properties, eventually, acting as
an inhibitor of polymorphonuclear leukocytes’ action, thus
inhibiting the release of reactive oxygen andnitrogen [39, 40].
A significant superoxide anion and NO-scavenging
capacity was detected for AeI and for AePF. This antioxi-
dant activity could be responsible for the anti-inflammatory
properties of Agrimonia eupatoria. Superoxide anion is an
inflammatorymediator and it reactswithNOoriginating per-
oxynitrite, which is a powerful oxidant that is also involved
in the inflammatory processes. This inflammatory mediator
acts throughdifferent pathways: inhibition of cytokine release
and peroxynitrite formation and inhibition of neutrophils
infiltration [41, 42]. Therefore, the significant superoxide
anion scavenging activity observed may also contribute to
the anti-inflammatory activity observed in the in vitro and
in vivo assays.
The acetic acid-induced writhing model induces the
release of endogenous mediators such as histamine, sero-
tonin, bradykinin, acetylcholine, substance P, and prostagl-
andins that are involved in both proinflammatory and
peripheral painmechanisms.Thismodel of pain is, therefore,
sensitive to the action of NSAIDs [43, 44]. For Agrimonia
eupatoria, the results suggest analgesic properties through
peripheral mechanisms. This fact is probably due to the anti-
inflammatory potential of agrimony.As these two physiologic
processes share many molecular mediators and mechanisms
[14], in some cases, their inhibition is concomitant. Actually,
this type of anti-inflammatory mechanism has already been
described in another species within the same genus, Agrimo-
nia pilosa [45, 46].
Regarding central analgesia, infusion and fraction of
agrimony showed no antinociceptive activity, not increasing
the animals’ reaction time on the hot plate. This supports
the hypothesis above for the shared mechanism between
analgesic and anti-inflammatory effects.
In the formalin test, the injection of formalin induces a
biphasic pain reaction in mice, the early and the late phases
[47]. The results are quantified as the time that the animals
spend licking the paw [48]. The absence of antinociceptive
effect of the AeI and AePF on early phase corroborates
the above data, suggesting that its analgesic properties are
not related to a modulation on the central nervous system.
On the other hand, the reduction of the time spent licking
on late phase supports the analgesia through peripheral
mechanisms.
The ethyl acetate fractioning process allowed us to obtain
a fraction with higher concentration of polyphenols. The fact
that there are no significant differences between the anti-
inflammatory and analgesic effects of AeI and AePF when
comparing their equivalent doses, that is, doses with the same
concentration of the compounds that are common to AeI
and AePF, suggests that the main compounds responsible for
these activities are probably the polyphenols of this fraction.
There are no signs of toxicity in the liver or kidneys
tissues, when comparing the histopathological images of the
tissues obtained from the control animals with the ones
treated with the infusion and its fraction. Although further
studies about this subject are needed, this data suggest an
absence of systemic toxic effects of the samples at concentra-
tions with therapeutic potential.
4. Conclusions
Antioxidant, anti-inflammatory, and peripheral analgesic
activities were observed for both the Agrimonia eupatoria
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Figure 6: Histological analysis of liver and kidney. Staining with hematoxylin; 20x magnification in the original. (a–c) Liver tissues obtained
from control animal (a); animal treated with reference drug (b); animal treated with AePF (c). (d–f) Renal tissues obtained from control
animal (d); animal treated with reference drug (e); animal treated with AePF (f).
infusion and/or its polyphenol-enriched fraction at non-
toxic doses for the liver and the kidneys. The polyphenol-
enriched fraction, essentially constituted by procyanidins
and flavonoids, namely, quercetin, kaempferol, apigenin, and
luteolin derivatives, was very active for all assays performed,
leading to the conclusion that polyphenols have a very
important role in these properties of Agrimonia eupatoria.
The results of the present work corroborate the traditional
use of the Agrimonia eupatoria infusion as antioxidant
and anti-inflammatory and suggests that its polyphenols
contribute to this activity, which may be helpful in devel-
oping novel and beneficial antioxidants, anti-inflammatory,
and/or peripheral analgesic agents. In addition, isoquercetin,
tiliroside, and kaempferol O-acetyl-hexosyl-O-rhamnoside
should be considered as lead molecules for designing new
pharmacophores, to be applied to the treatment of oxidation-
and inflammation-related pathologies.
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